BDSX Biodesix

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference

LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025.

Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference

Date: Thursday, September 11, 2025

Location: New York, NY

1x1 meetings only

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
05/09/2025

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

Jonathan Moreland
  • Jonathan Moreland
Free Trial
KRNY Kearny Financia...
ASA ASA ... (+10)

InsiderInsights.com Daily Ratings Report: September 23, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

KRNY KEARNY FINANCIAL CORP.
ASA ASA
CULP CULP INC.
MUX MCEWEN MINING INC.
AROC ARCHROCK INC.
BCDA BIOCARDIA
AOUT AMERICAN OUTDOOR BRANDS
BDSX INC.
BUKS BIODESIX
BUTLER NATIONAL CORP
09/24/25 September 24, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces One-for-Twenty Reverse Stock Split

Biodesix Announces One-for-Twenty Reverse Stock Split LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the ...

September 11, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Bes...

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025. Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference Date: Thursday, September 11, 2025Location: New York, NY1x1 meetings only About Biodesix ...

September 5, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence...

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix ...

August 19, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Second Quarter 2025 Results and Highlights

Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. “We had strong second qu...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch